PML risk stratification using anti-JCV antibody index and L-selectin

Multiple Sclerosis

Volumn 22, Issue 8, 2016, Pages 1048-1060

  Schwab, Nicholas ^a   Schneider Hohendorf, Tilman ^a   Pignolet, Béatrice ^b   Spadaro, Michela ^c   Görlich, Dennis ^a   Meinl, Ingrid ^d   Windhagen, Susanne ^e   Tackenberg, Björn ^f   Breuer, Johanna ^a   Cantó, Ester ^g   Kümpfel, Tania ^d   Hohlfeld, Reinhard ^d   Siffrin, Volker ^h   Luessi, Felix ^h   Posevitz Fejfár, Anita ^a   Montalban, Xavier ^g   Meuth, Sven G ^a   Zipp, Frauke ^h   Gold, Ralf ⁱ   Du Pasquier, Renaud A ^j   Kleinschnitz, Christoph ^k   Jacobi, Annett ^a,l   Comabella, Manuel ^g   Bertolotto, Antonio ^c   Brassat, David ^b,m   Wiendl, Heinz ^a   more..

^a UNIVERSITY OF MÜNSTER   (Germany)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF MUNICH   (Germany)

^e Department of Neurology   (Germany)

^f UNIVERSITY HOSPITAL GIESSEN   (Germany)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h JOHANNES GUTENBERG UNIVERSITY   (Germany)

ⁱ RUHR UNIVERSITY BOCHUM   (Germany)

^j LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^k UNIVERSITY OF WÜRZBURG   (Germany)

^l BRANDENBURG MEDICAL SCHOOL THEODOR FONTANE   (Germany)

^m BioNAT Study Group   (France)

more..

Author keywords

CD62L; JCV index; L selectin; Natalizumab; PML; risk stratification

Indexed keywords

JCV ANTIBODY; L SELECTIN; NATALIZUMAB; UNCLASSIFIED DRUG; VIRUS ANTIBODY; ANTI JCV ANTIBODY; ANTIBODY; BIOLOGICAL MARKER; SELL PROTEIN, HUMAN;

ALGORITHM; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; HUMAN; HUMAN CELL; JC VIRUS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; RISK STRATIFICATION; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; ANALYTICAL PARAMETERS; ANTI JCV ANTIBODY INDEX; BLOOD SAMPLING; CRYOPRESERVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; VALIDATION PROCESS; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; EUROPE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; OPPORTUNISTIC INFECTION; SEROLOGY; TREATMENT OUTCOME; VIROLOGY;

ALGORITHMS; ANTIBODIES, VIRAL; BIOMARKERS; EUROPE; HUMANS; IMMUNOCOMPROMISED HOST; JC VIRUS; L-SELECTIN; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS; NATALIZUMAB; OPPORTUNISTIC INFECTIONS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEROLOGIC TESTS; TREATMENT OUTCOME;

EID: 84978152301     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458515607651     Document Type: Article

References (27)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
2. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23.
3. Tan CS, Koralnik IJ,. Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: Clinical features and pathogenesis. Lancet Neurol 2010; 9: 425-437.
4. Biogen. Biogen Idec Medical information., https://medinfo.biogenidec.com/ (2015,. accessed 3 June 2015).
5. Calabrese LH, Molloy E, Berger J,. Sorting out the risks in progressive multifocal leukoencephalopathy. Nat Rev Rheumatol 2015; 11: 119-123.
6. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870-1880.
7. Cutter GR, Stüve O,. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence? Mult Scler 2014; 20: 1304-1305.
8. Kalincik T, Horakova D, Spelman T, et al. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol 2015; 77: 425-435.
9. Capobianco M, di Sapio A, Malentacchi M, et al. No impact of current therapeutic strategies on disease reactivation after natalizumab discontinuation: A comparative analysis of different approaches during the first year of natalizumab discontinuation. Eur J Neurol 2015; 22: 585-587.
10. Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol 2014; 76: 802-812.
11. Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 2013; 81: 865-871.
12. Major EO, Douek DC,. Risk factors for rare diseases can be risky to define: PML and natalizumab. Neurology 2013; 81: 858-859.
13. Schneider-Hohendorf T, Philipp K, Husstedt IW, et al. Specific loss of cellular L-selectin on CD4(+) T cells is associated with progressive multifocal leukoencephalopathy development during HIV infection. AIDS 2014; 28: 793-795.
14. Lee P, Plavina T, Castro A, et al. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol 2013; 57: 141-146.
15. Brady HJM,. Apoptosis methods and protocols. Totowa, NJ: Humana, 2004.
16. Chrest FJ, Buchholz MA, Kim YH, et al. Identification and quantitation of apoptotic cells following anti-CD3 activation of murine G0 T cells. Cytometry 1993; 14: 883-890.
17. Kuesters G,. Anti-JC virus (JCV) antibody index differentiates risk of PML in natalizumab-treated MS patients with no prior immunosuppressant use: An updated analysis. Neurology 2015; 84: AAN Poster P4 031.
18. Meira M, Sievers C, Hoffmann F, et al. MiR-126: A novel route for natalizumab action? Mult Scler 2014; 20: 1363-1370.
19. Villar LM, Costa-Frossard L, Masterman T, et al. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Ann Neurol 2015; 77: 447-457.
20. Basnyat P, Hagman S, Kolasa M, et al. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients. Mult Scler Relat Disord 2015; 4: 334-338.
21. Bohl DL, Brennan DC, Ryschkewitsch C, et al. BK virus antibody titers and intensity of infections after renal transplantation. J Clin Virol 2008; 43: 184-189.
22. Pastrana DV, Brennan DC, Cuburu N, et al. Neutralization serotyping of BK polyomavirus infection in kidney transplant recipients. PLoS Pathog 2012; 8: e1002650.
23. Pastrana DV, Wieland U, Silling S, et al. Positive correlation between Merkel cell polyomavirus viral load and capsid-specific antibody titer. Med Microbiol Immunol 2012; 201: 17-23.
24. Lieberman L,. CD62L (L-selectin) is not a reliable biomarker for predicting risk of PML in natalizumab-treated MS patients. Neurology 2015; 84: AAN Poster P4 0.39.
25. Spadaro M, Caldano M, Marnetto F, et al. Natalizumab treatment reduces L-selectin (CD62L) in CD4(+) T cells. J Neuroinflammation 2015; 12: 146.
26. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: Implications for PML risk stratification. Ann Neurol 2010; 68: 295-303.
27. Jackson LA, Drevets DA, Dong ZM, et al. Levels of L-selectin (CD62L) on human leukocytes in disseminated cryptococcosis with and without associated HIV-1 infection. J Infect Dis 2005; 191: 1361-1367.